Oramed Pharmaceuticals ROE 2024

Oramed Pharmaceuticals Aktienanalyse

What does Oramed Pharmaceuticals do?

Oramed Pharmaceuticals Inc is an innovative biotech company headquartered in Jerusalem, Israel. The company was founded in 2006 by Nadav Kidron and specializes in the development of oral forms of protein-based therapeutics. The idea behind Oramed Pharmaceuticals was to revolutionize the way proteins are administered. Typically, protein-based drugs like insulin need to be administered in injectable form, which can be unpleasant and painful for many patients. Oramed Pharmaceuticals set out to find a solution to this problem. The company has developed a technology called ORMD-0801, which allows for the oral administration of insulin. The active ingredient is protected by a special capsule that monitors the pH level in the stomach. Once the capsule reaches the small intestine, the active ingredient is released and can be absorbed by the body. Oramed Pharmaceuticals aims to improve the treatment of diabetes. With the oral form of insulin, patients can take their medication much easier and more conveniently. This can help improve treatment and increase patients' quality of life. In addition to the development of ORMD-0801, Oramed Pharmaceuticals is also working on developing oral forms of other protein-based therapeutics. The company has filed a variety of patents for technologies and therapies and actively collaborates with other companies and research institutions. Oramed Pharmaceuticals has two main divisions: the development department and the commercialization department. The development department is responsible for the research and development of new therapies, while the commercialization department is responsible for sales and marketing of the products. Oramed Pharmaceuticals' business model is focused on developing innovative therapies and bringing them to market. The company works closely with other companies and research institutions to advance the development of new therapies. Oramed Pharmaceuticals is currently working on several projects to develop additional orally administered protein-based therapeutics. In addition to insulin, the company is also working on proteins that can be used in the treatment of other diseases such as osteoporosis and Parkinson's. The products of Oramed Pharmaceuticals are of great importance to both patients and the medical community. The oral forms of protein-based therapeutics can help make the treatment of diabetes and other diseases much easier and more convenient. This can help increase patient satisfaction and improve compliance. In recent years, Oramed Pharmaceuticals has received several awards and accolades for its innovative products. The company continues to work on developing new therapies and changing the way medication is administered. Oramed Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Oramed Pharmaceuticals's Return on Equity (ROE)

Oramed Pharmaceuticals's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Oramed Pharmaceuticals's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Oramed Pharmaceuticals's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Oramed Pharmaceuticals’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Oramed Pharmaceuticals stock

What is the ROE (Return on Equity) of Oramed Pharmaceuticals this year?

The ROE of Oramed Pharmaceuticals this year is 0.03 undefined.

How has the Return on Equity (ROE) of Oramed Pharmaceuticals developed compared to the previous year?

The ROE of Oramed Pharmaceuticals has increased by -114% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Oramed Pharmaceuticals?

A high ROE indicates that Oramed Pharmaceuticals generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Oramed Pharmaceuticals?

A low ROE can indicate that Oramed Pharmaceuticals is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Oramed Pharmaceuticals affect the company?

A change in ROE (Return on Equity) of Oramed Pharmaceuticals can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Oramed Pharmaceuticals?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Oramed Pharmaceuticals?

Some factors that can influence Oramed Pharmaceuticals's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Oramed Pharmaceuticals pay?

Over the past 12 months, Oramed Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oramed Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Oramed Pharmaceuticals?

The current dividend yield of Oramed Pharmaceuticals is .

When does Oramed Pharmaceuticals pay dividends?

Oramed Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oramed Pharmaceuticals?

Oramed Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Oramed Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oramed Pharmaceuticals located?

Oramed Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oramed Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oramed Pharmaceuticals from 11/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.

When did Oramed Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/5/2024.

What was the dividend of Oramed Pharmaceuticals in the year 2023?

In the year 2023, Oramed Pharmaceuticals distributed 0 USD as dividends.

In which currency does Oramed Pharmaceuticals pay out the dividend?

The dividends of Oramed Pharmaceuticals are distributed in USD.